



NORA- NEW TOOLS FOR THE JOB? ANOTHER ROAD TO ROME

George Gilkey MD
Assistant Professor
Division of Cardiovascular Anesthesia

Minnesota Society of Anesthesiologists
Fall Meeting 2022



Disclosures

- No financial disclosures
- OFF-Label use of medication WILL be discussed – clearly labelled

Goals and objectives

- By the end of this conference, participants should be able to:
- Recognize the unique pharmacokinetic and pharmacodynamic properties of Remimazolam
- Distinguish which clinical applications will best suit the pharmacological profile of Remimazolam

NORA: Challenges

- Airway Management
- Useful Help
- Limited PACU / Recovery resources
- Time Pressure
- Production Pressure
- Transitions to higher level of care
- Distance from higher level of care (miles, not meters?)



NORA Formulation Wish List

- Rapid onset
- Predictable
- Rapid offset
- Minimal Respiratory effects
- Minimal CV effects
- Multiple routes of administration
- Cheap
- Available

Drug Development:

- Phase I trials: 2012
- Phase II 2015
- Phase III: 2018
- Remimazolam approved for use in Japan 2020
 - Approved for use in US: July 2020
 - Approved for use in EU: March 2021
- First use at Mayo clinic: July 2021

PHARMACOLOGY



Image copyright GettyImages

Remimazolam

Formulation

- 20mg lyophilized powder
- Reconstitute in saline 8.2mL - >2.5mg/mL
- For IV injection
- Reconstituted in vial: stable 8 hrs room temp




Byfavo.com

Remimazolam:

Physiochemical Properties


- Additional Ester linkage
- pH 2.9-3.9 in saline



British Journal of Anaesthesia, 127 (1):
41e55 (2021)

Remimazolam:

Metabolism



- Ester linkage hydrolyzed:
 - Tissue esterase
 - Carboxylesterase1 (CES1)
 - Hepatic
- Inactive metabolite:
 - CNS 7054

Remimazolam

Formal Pharmacokinetics

- Volume of distribution: $34 \pm 9.4\text{L}$
- Terminal Half-life: $45\text{min} \pm 9\text{min}$
- Clearance time independent of body mass

Practical Pharmacokinetics

- Onset and offset:
 - 1-2 minutes for onset
 - Offset: dose dependent.
 - single dose: 10 min
 - Infusion(**off label**): 10-20 min

Remimazolam

Pharmacology: Bioavailability

- PO
 - 100% absorption as a liquid
 - 1.2% bioavailability PO
 - 1st pass metabolism
 - Even 480mg of PO remimaz had minimal CNS effects (24vials...)
 - Bitter taste
- Low likelihood to be used in drug facilitated sexual assault

Remimazolam

Pharmacology: Bioavailability

- Study: 12 male volunteers “...only with experience of intranasal drug administration included”
 - Intranasal: **Powder**: 10, 20, 40mg
 - 50% bioavailable
 - Elimination: 0.7-0.9hr
 - Intranasal **Solution**(2.5mg/mL):
 - 47% (low volume) 26%(high volume)
 - Nasal/Sinus pain prohibitive


Remimazolam

Administration

- Dosing:
 - ASA 1-2: 5mg IV with 2.5mg Q2min PRN
 - ASA 3+: 2.5mg with 1.25-2.5 Q2 PRN
- Induction for GA:
 - 0.1-0.3mg/kg (OFF LABEL)
- Contraindications:
Allergy to dextran 40 (part of the formulation)

Off Label in US: Infusion Kinetics

- Infusion for general anesthesia
 - Induction:
 - 12mg/kg/hr
 - 6mg/kg/hr (15-20s slower)
 - Maintenance:
 - 1-3mg/kg/hr



Lohmer et al. The Journal of Clinical Pharmacology 2020, 60(4) 505–514

Patient Subsets:



The unknowns:

- Pediatrics –no published studies on pediatric patients
- Obstetrics: unknown placental transfer
- Lactating Women- no published data on presence of remimazolam in breast milk or nursing infant
- Extremes of hepatic dysfunction -
 - European packaging recommends dose reduction
 - Case report of prolonged sedation with Child-Pugh score of 11

Unusual Complications

IV compatibility

- Remimazolam forms precipitates in:
 - Lactated Ringer's
 - Acetated Ringer's
- Concentration 5mg/ml
 - -US concentration 2-2.5mg/mL
- pH dependent



Sasaki et al. Br J Anaesth. 2021 Mar;126(3):e87-e89



Procedural Use




Remimazolam in Cardiac Surgery TAVR

- Myoshi et al:
- 42 TAVR pts under GA
 - Remimaz + Remifentanil
 - Prop/sevo + Reminfentanil
 - Midaz/prop TIVA + Remifentanil

Miyoshi et al. Biomed Res Int. 2022 Oct 22;2022

Remimazolam in TAVI



Miyoshi et al. Biomed Res Int. 2022 Oct 22;2022

Less Norepinephrine in Remimazolam group

HR lower in Remimazolam group

What about delirium?

- Aoki et al:
 - 200 CV surgery pt
 - 78 remimaz infusion +remifentanil
 - 122 TIVA/volatile
 - CPB, AAA, endovascular

Results:

No changes in MMSE
No difference in delirium

Caveat: small, observational,
potential confounders

Aoki et al. Association between remimazolam and postoperative delirium. Journal of Anesthesia. Published online 12 oct 2022

Remimazolam

Procedural Uses

- GI endoscopy
 - LVAD patients
 - ALS PEG tube patients
 - Feeding tube w/ odynophagia
- Cardiac Cath Lab:
 - Cardioversion
 - Congenital Percutaneous interventions
 - Trans-carotid TAVR
- Interventional Radiology
 - - vascular access w/ poor CV status
 - vascular stenting, angiography
- PICC/HD catheter placement
- ultrasound guided procedures needing quick sedation
- - CT guided quicker procedures (bone biopsies, etc)
- Neurosurgical/ Neuro IR outpatient procedures:
 - - trigeminal ablations

Remimazolam

Procedural Advantages

- Very hemodynamically stable:
 - Minimal changes to SVR
 - Minimal Changes to HR
 - No rhythm disturbances
- Minimal respiratory depression
 - Spontaneous respiration preserved
- Rapid emergence
- Easily titrated due to short duration
- Reversible with flumazenil if needed

Remimazolam


Procedural Disadvantages

- Short duration = frequent dosing
 - Manage provider expectations
- IV compatibility issues
- \$\$

Conclusions:

- Pros and Cons: Context dependent
- Con: \$
- Very titratable
- Reversible
- Quick wakeup with minimal grogginess
- Good hemodynamic profile
- Minimal respiratory depression when used as solo agent

QUESTIONS & ANSWERS



Gilkey.George@mayo.edu

